Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsBrandon Couillard - Managing DirectorCasey Woodring - Vice President Equity ResearchDoug Schenkel - Managing Director, Life Science Tools, and DiagnosticsJacob Johnson - VP and Head of Investor RelationsJason Garland - CFOOlivier Loeillot - President and CEOPhilip Boyd - Senior Managing DirectorSubbu Nambi - Managing Director and Healthcare Equity ResearchNone - Company RepresentativeConference Call Participants ...

Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsBrandon Couillard - Managing DirectorCasey Woodring - Vice President Equity ResearchDoug Schenkel - Managing Director, Life Science Tools, and DiagnosticsJacob Johnson - VP and Head of Investor RelationsJason Garland - CFOOlivier Loeillot - President and CEOPhilip Boyd - Senior Managing DirectorSubbu Nambi - Managing Director and Healthcare Equity ResearchNone - Company RepresentativeConference Call Participants ...

Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Speaker12I would now like to turn the conference over to Jacob Johnson, Vice President, Investor Relations. You may begin.Speaker5Thank you, operator, and welcome everyone to our 2025 fourth quarter report. On this call, we will cover business highlights and financial performance for the three and 12-month periods ended December 31st, 2025, and we'll provide financial guidance for the full year 2026. Joining us on the call today ar ...